Skip to main content
. 2024 Aug 29;89:102020. doi: 10.1016/j.molmet.2024.102020

Figure 1.

Figure 1

Systemic ADI-PEG20 treatment decreases body weight and lowers fasting blood glucose. (A) Body weights of db/db mice treated twice weekly with IP injections of ADI-PEG20 or PEG20 over the course of the 4-week study (n = 10–11/group). (B) Body weights of db/db mice and lean Db/+ mice treated by IM injection during the 12-week study (n = 9–10/group). (C) Fasting blood glucose levels measured during the 12-week study (n = 5–10/group). ∗p < 0.05 for db/db ADI-PEG20 vs db/db PEG20, #p < 0.05 for Db/+ PEG20 vs db/db ADI-PEG20.